|1.||Kim, Ji Hoon: 1 article (10/2005)|
|2.||Hwang, Byung Gil: 1 article (10/2005)|
|3.||Min, Byung-Il: 1 article (10/2005)|
|4.||Kim, Sun Kwang: 1 article (10/2005)|
|5.||Park, Dong Suk: 1 article (10/2005)|
|6.||Na, Heung Sik: 1 article (10/2005)|
|7.||Park, Jung Hyuk: 1 article (10/2005)|
|8.||Bae, Sang Jin: 1 article (10/2005)|
|9.||Zhuang, D-B: 1 article (01/2002)|
|10.||Lunderberg, T: 1 article (01/2002)|
01/01/1993 - "5. A 5-hydroxytryptamine3 (5-HT3) receptor antagonist, MDL 72222 (1 mg kg-1), reduced emesis when given alone and combined with metoclopramide (low dose). "
02/01/1992 - "PBG-induced vomiting was blocked by the 5-HT3 receptor antagonist MDL 72222. "
11/01/1995 - "MDL 72222 blocked ipecac-induced vomiting in a dose-related manner and was partially effective in attenuating cisplatin-induced emesis. "
05/12/1994 - "On the other hand, blocking 5-HT3 receptors with MDL 72222 (0.5 and 5 mg/kg, i.v.) or low doses (0.01 mg/kg i.v.) of ICS 205-930 had no apparent effect on the vomiting induced by copper sulfate. "
07/01/1986 - "MDL 72222, the selective 5-hydroxytryptamine (5-HT) M-receptor antagonist, prevented or reduced cisplatin-induced emesis in ferrets. "
01/01/1995 - "Bemesetron significantly reduced catalepsy at a dose of 1 mg/kg, whilst 10 mg/kg potentiated the phenomenon and 0.1 mg/kg was found to be without effect. "
01/01/1995 - "The aim of this study was to examine the effects of bemesetron and granisetron, two selective 5-HT3 receptor antagonists, on this catalepsy in mice. "
07/01/1990 - "MDL 72222 had no effect on the bradycardia associated with embolization; however, it significantly reduced the decrease in arterial blood pressure and converted the decrease in tidal volume seen in pulmonary embolism to an increase. "
06/01/1987 - "In the absence of MDL 72222 the reflex bradycardia partially concealed a positive chronotropic response to 5-HT. "
09/01/1986 - "Treatment with MDL 72222, 0.3 mg/kg i.v., abolished the initial depressor response and bradycardia produced by 5-HT. "
07/14/1988 - "The bradycardia was unaffected by the 5-HT3 antagonist, MDL 72222, but was reversed by atropine and was abolished in bi-vagotomised cats. "
08/01/1985 - "Administration of MDL 72222, a selective antagonist of M-type 5-HT receptors, blocked bradycardia elicited by 5-HT without affecting that caused by stimulation of the vagus nerve. "
09/01/1994 - "4. The tachycardia was not affected by MDL 72222, metoclopramide and cocaine. "
05/01/1998 - "Two 5-HT3 receptor antagonists (ondansetron and MDL-72222) blocked hypotension and restored tachycardia, basic features of orthostatic adaptation of the circulatory system. "
01/01/1989 - "In contrast, atenolol antagonized this tachycardia and the 5-HT antagonists methysergide, ketanserin and MDL 72222 reduced it. "
06/01/1987 - "After blockade of the bradycardia response by MDL 72222, 5-HT elicited a significant tachycardia, which was not altered by propranolol and phentolamine, but was prevented by phenoxybenzamine. "
01/01/1992 - "The 5-HT1 receptor antagonists, pindolol and spiroxatrine, the 5-HT3 receptor antagonist MDL 72222 and the alpha 2-adrenoceptor blocking agent idazoxan failed to antagonize the tachycardia induced by 5-HT. "
04/01/1989 - "However, ICS-205-930, MDL-72222 and GR-38032F all produced dose-dependent analgesia in the chemical pain test, that was not altered by systemic naloxone administration (1 mg/kg, s.c.). "
10/24/1989 - "Intraplantar administration of serotonin 5-HT3 receptor antagonists ICS 205-930 and MDL 72222 (1-100 micrograms; 50 microliters) produced dose-related analgesia against formalin-induced acute- and Freunds adjuvant-induced chronic-inflammatory pain in rats. "
|2.||Ipecac (Syrup of Ipecac)
|3.||5-HT3 Serotonin Receptors (5 HT3 Receptor)
|5.||Serotonin (5 Hydroxytryptamine)
|9.||Serotonin 5-HT3 Receptor Antagonists
|3.||Induced Hyperthermia (Thermotherapy)
|4.||Drug Therapy (Chemotherapy)